Merck & (MRK) Fundamentals 2026 — P/E 35.9x, Revenue Analysis | SniperIQ
Merck & (MRK) is a US-listed Healthcare company in Drug Manufacturers - General with a market capitalization of
Merck & (MRK) is a US-listed Healthcare company in Drug Manufacturers - General with a market capitalization of
Merck & (MRK) has a market capitalization of approximately
Merck &'s trailing twelve-month P/E ratio is 35.9x, with a price-to-book (P/B) of 6.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Merck & runs a net profit margin of 13.6%, a gross margin of 75.9%, and an operating margin of 27.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Merck & reported revenue of $64.9B for fiscal year 2025, with net income of
Merck & offers a trailing dividend yield of about 2.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Merck & carries a debt-to-equity ratio of 1.07x and a current ratio of 1.30x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Merck & (MRK) the key facts are: market cap
Get Merck &'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.